Aldeyra Therapeutics, Inc. (FRA:137)
Germany · Delayed Price · Currency is EUR | Market Cap | 212.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.81M |
| Shares Out | n/a |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 288 |
| Open | 3.535 |
| Previous Close | 3.580 |
| Day's Range | 3.483 - 3.644 |
| 52-Week Range | 1.302 - 6.416 |
| Beta | n/a |
| RSI | 39.85 |
| Earnings Date | Mar 2, 2026 |
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment... [Read more]
News
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst
Aldeyra Therapeutics Inc Regulatory Update Conference Call Transcript
Aldeyra Therapeutics Inc Regulatory Update Conference Call Transcript
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxalap
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxalap
Aldeyra drops as FDA delays review of marketing application for lead drug
Aldeyra Therapeutics (ALDX) stock slips as the company faces an FDA review delay for its lead drug reproxalap in dry eye disease. Read more here.
FDA Extends Review Timeline For Aldeyra's Reproxalap NDA In Dry Eye Disease
(RTTNews) - Aldeyra Therapeutics Inc. (ALDX) announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target action date for the New Drug Applicatio...
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases
Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
ALDX: BTIG Reiterates Buy Rating with Price Target Maintained at $9.00 | ALDX Stock News
ALDX: BTIG Reiterates Buy Rating with Price Target Maintained at $9.00 | ALDX Stock News
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise...
Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results
Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive we...
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexat...
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 ...
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexat...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug...
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data
Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for Decem...